FRESENIUS KABI ONCOLOGY LTD. - Updates on Delisting Offer

DSP Merrill Lynch Ltd ("Manager to the Delisting Offer") on behalf of Fresenius Kabi (Singapore) Pte Ltd (Acquirer) has informed this Second Corrigendum to the Public Announcement ("Second Corrigendum") dated September 16, 2013 to the shareholders of Fresenius Kabi Oncology Ltd (Target Company) in respect of the proposed acquisition by Acquirer and consequent delisting of the fully paid-up equity shares of the Target Company with a face value of Re. 1 each (Shares") from the BSE Limited and the National Stock Exchange of India Limited in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 and to the letter of offer issued in respect thereof inviting Bids from all Public Shareholders of the Company (Letter of Offer"), is in continuation of and should be read in conjunction with the PA, the Letter of Offer and the first corrigendum to the PA and the Letter of Offer published on October 13, 2013 in the same newspapers in which the PA was published ("First Corrigendum").<br/><br/>The capitalised terms and abbreviations used in this Second Corrigendum and not defined herein have the same meaning as ascribed to them in the PA and the Letter of Offer, unless otherwise specified.